© Copyright 2001-2020 Erowid Center. DrugsData is a project of
Erowid Center. All rights reserved.
By using this site you agree not to publish its images, data, results, or analysis of its results without written permission from Erowid Center.
Permission is required before using data from DrugsData in any of these ways, including importing it into public or shared databases, software, or systems.
This policy has been in place since 2001 in order to require cooperation and credit by researchers and app authors.
Your javascript is turned off.
To remove this message, turn on javascript and accept the Terms of Use.
Our current GC/MS protocol can not distinguish between metamizole and 4-methylaminoantipyrine. 4-Methylaminoantipyrine is a metabolite of metamizole. Their mass spectra are indistinguishable because metamizole undergoes thermal decomposition to 4-methylaminoantipyrine and aminopyrine during GC-MS analysis. The chemical identified in this sample could be either Metamizole or 4-Methylaminoantipyrine, or a combination of the two.
Dec 11 2019: We're ordering the standard for 4-methylaminoantipyrine so we can be more certain about the identification.
Dec 9, 2019: Now with the metamizole standard in-hand at the lab, the spectrum and compound originally identified in this sample as 4-methylaminoantipyrine has been revised to metamizole.4-methylaminoantipyrine is a metabolite of metamizole and has a very similar mass spectrum. Although it is theoretically possible the chemical in this sample could be the compound 4-methylaminoantipyrine, it's less likely to be that since it's the metabolite and our main analytical toxicologist believes the new identification is correct.
Dec 4, 2019: A reference standard is available for metamizole, and has been ordered for the lab to test it and see how it behaves in their GC, and whether it shows up like this sample did.